Examination of end-point tumour burden in Dox-treated or -untreated groups (n=10 per group) demonstrated that depletion of USP13 resulted in profound decreases in tumour weight (78.5% reduction, P<0.001) and number of nodules (68.7% reduction, P<0.001; Fig. 8b). The gene discussed is USP13; the disease is neoplasm.